Clinical lymphoma, myeloma & leukemia · 2024
The Impact of Clinical Features on Survival and Relapse of Patients Diagnosed With T-cell Acute Lymphoblastic Leukemia - a Multicenter Cohort Study.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
da Silva Diego Luz Felipe, Duarte Bruno Kosa Lino, de Oliveira Yve Cardoso, Piaia Camila, Aragão Jordana Santos Ramires, Chapchap Eduardo Cerello, de Carvalho Maria Eduarda Alonso Joaquim, Mauad Vitor Augusto Queiroz, Velloso Elvira Drp, Batista Renata Lyrio Rafael, Massaut Ires Hamyra Bezerra, Kerbauy Fabio Rodrigues, Hamerschlak Nelson, Rocha Vanderson, Rego Eduardo M, Silva Wellington F
Аннотация
BACKGROUND: T-cell acute lymphoblastic leukemia (T-ALL) remains understudied compared to B-cell ALL, especially in Latin America. Different biology and response to chemotherapy have been described.
METHODS: This retrospective multi-site cohort study analyzed data from 152 newly diagnosed T-ALL patients aged 15 years and above, between January 2010 and June 2022.
RESULTS: The median age was 30 years, with 53.9% of the patients presenting thymic T-ALL. Asparaginase-based regimens were used in 80.5% of patients. Five-year overall survival (OS) and event-free survival (EFS) were 44.3% and 41%, respectively. Thymic (CD1a) phenotype (HR 0.50 [0.28-0.89], P = .019) and asparaginase-based regimens (HR 0.53 [0.32-0.88], P = .014) were associated with improved OS, while older age predicted inferior OS (HR 1.02, P = .017). The 60-day cumulative incidence of thrombosis was 19.5% and induction death rate of 11.2%.
CONCLUSIONS: The study provides real-world multicenter Brazilian data on adult T-ALL, which might represent Latin America's scenario, also highlights the benefits of pediatric-inspired regimens, especially for younger adults, key prognostic factors and that awareness is needed to manage thrombotic/death risks in the early treatment phases to improve outcomes.
METHODS: This retrospective multi-site cohort study analyzed data from 152 newly diagnosed T-ALL patients aged 15 years and above, between January 2010 and June 2022.
RESULTS: The median age was 30 years, with 53.9% of the patients presenting thymic T-ALL. Asparaginase-based regimens were used in 80.5% of patients. Five-year overall survival (OS) and event-free survival (EFS) were 44.3% and 41%, respectively. Thymic (CD1a) phenotype (HR 0.50 [0.28-0.89], P = .019) and asparaginase-based regimens (HR 0.53 [0.32-0.88], P = .014) were associated with improved OS, while older age predicted inferior OS (HR 1.02, P = .017). The 60-day cumulative incidence of thrombosis was 19.5% and induction death rate of 11.2%.
CONCLUSIONS: The study provides real-world multicenter Brazilian data on adult T-ALL, which might represent Latin America's scenario, also highlights the benefits of pediatric-inspired regimens, especially for younger adults, key prognostic factors and that awareness is needed to manage thrombotic/death risks in the early treatment phases to improve outcomes.